Vanillin attenuated ferroptosis in ropivacaine-induced SH-SY5Y cells by targeting phosphodiesterase 4B
Аннотация
Ropivacaine, a widely used local anesthetic, can induce neurotoxicity at high concentrations, but effective interventions remain limited, and ferroptosis has been implicated in this process. Vanillin, a natural phenolic compound with neuroprotective properties, was investigated for its effects on ropivacaine-induced ferroptosis in SH-SY5Y human neuroblastoma cells. An in vitro model of neurotoxicity was established using 5 mM ropivacaine, and vanillin (50 and 100 nM) dose-dependently reversed ropivacaine-induced reductions in cell viability and proliferation, suppressed lipid peroxidation markers (MDA, ROS, 4-HNE) and iron accumulation, replenished GSH levels, and restored the expression of anti-ferroptotic proteins GPX4, SLC7A11, and FTH1 while downregulating TFR1. Computational target prediction and molecular docking identified phosphodiesterase 4B (PDE4B) as a candidate binding target of vanillin. Mechanistically, vanillin promoted proteasome-dependent degradation of PDE4B without altering its mRNA expression, as demonstrated by the reversal of vanillin-induced PDE4B downregulation by the proteasome inhibitor MG132. Vanillin also suppressed ropivacaine-induced upregulation of TLR4 and p38 MAPK phosphorylation. Crucially, PDE4B overexpression abolished the protective effects of vanillin, reinstating lipid peroxidation, iron overload, GSH depletion, and the aberrant expression of ferroptosis-related proteins. Collectively, these findings demonstrate that vanillin attenuates ropivacaine-induced ferroptosis in SH-SY5Y cells by targeting PDE4B for proteasomal degradation and inhibiting the downstream TLR4/p38 MAPK signaling pathway, identifying vanillin as a promising neuroprotective agent and PDE4B as a potential therapeutic target for local anesthetic-induced neurotoxicity.